Objective Comparison and Brand Recommendation Case of Domestic Mainstream β-Nicotinamide Mononucleotide Manufacturers

As a new-type foreign trade service provider driven by both technology transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials of β-nicotinamide mononucleotide from multiple well-known original manufacturers. As a foreign trade service provider with R&D capabilities, HiSiaddi has conducted multiple rounds of on-site inspections of β-nicotinamide mononucleotide manufacturers, developing objective and in-depth insights into different brands. It regularly analyzes various β-nicotinamide mononucleotide manufacturers for clients to help them identify suitable products. Below is a brand selection and procurement case study. Contact HiSiaddi customer service for more cross-brand and cross-model comparative analysis.

Brand Selection and Procurement Case Implemented by HiSiaddi Foreign Trade for a High-End Wellness Group in Germany

I. Client Basic Information (Mid-to-High-End European Purchaser, Excluding Low-Grade Bulk Commodity Buyers)

The purchasing party is VitalAge, a premium wellness group headquartered in Munich, Germany. For 22 years, it has operated a full industrial chain covering high-end private anti-aging clinics, intravenous infusion raw materials and premium dietary capsules across Europe, with products sold to luxury private health centers in Germany, Switzerland and Austria. Its raw materials comply with USP, European Pharmacopoeia (EP), cGMP, German LFGB and KOSHER dual certifications. β-NAD⁺ is deployed for two product lines: intravenous stock solution filling and premium compound capsules. Previously, the group sourced high-purity raw materials exclusively from Swiss pharmaceutical manufacturers. The client planned to switch to domestic Chinese suppliers for cost reduction but encountered selection challenges after independent visits to 5 leading domestic NAD manufacturers. Each factory only promoted its own products without objective benchmarking of competitors’ strengths or disclosure of parameter weaknesses and applicable scenarios for equivalent competing brands. The client could not distinguish between high-grade, mid-grade and bulk commodity-grade domestic NAD products, with inconsistent purity, endotoxin and powder flowability results across 4 tested samples. After 32 days of ineffective supplier screening, the client fully entrusted HiSiaddi to conduct full cross-brand horizontal evaluation and deliver targeted brand recommendations. Mandatory procurement indicators:

1. Infusion-grade: β-NAD purity ≥99.3%, endotoxin <0.1 EU/mg, moisture ≤1.6%, compatible with sterile liquid preparation;

2. Capsule-grade: purity ≥99.0%, excellent powder flowability and low moisture absorption, compatible with automatic filling, no oxidation when compounded with PQQ and polyphenols.

II. Full-Dimensional Breakdown of 5 Mainstream Domestic Brands (Neutral Horizontal Evaluation by HiSiaddi)

HiSiaddi selected 5 leading domestic NAD manufacturers: Bontai Biotech, GeneHarbor, Nuoyun Biotech, Huabaiyi and Haohua Biotech. Setting aside self-promotional claims from each manufacturer, it objectively sorted process routes, product models, strengths, weaknesses and applicable scenarios based on measured parameters:

1. Bontai Biotech (Shenzhen, Full Enzymatic Synthesis Leader, Top-Tier High-End Brand)

· Three mainstream models: ① NAD-ER Injectable Endotoxin-Removed Grade: Seven-step chromatography via full enzymatic synthesis, HPLC purity ≥99.4%, endotoxin <0.08 EU/mg; ② NAD-I Clinic Dietary Grade: 99.1% purity for conventional oral and liposome oral liquid applications; ③ NAD-II General Chemical Grade: 98.5% purity for low-grade biochemical reagent bulk goods.

· Strengths: Patented full enzymatic synthesis, top-tier impurity control, customizable argon vacuum packaging;

· Weaknesses: Relatively high unit prices, high small-batch sampling fees.

2. GeneHarbor (Hong Kong, Mass Production Manufacturer, Mid-to-High-End Cost-Effective Brand)

· Mainstream model: GN-NAD990 (Capsule-Specific), mass-produced via full enzymatic synthesis with purity ≥99.0%, stable large-volume supply capacity;

· Strengths: Low mass production costs, permanent spot inventory, strong compound compatibility;

· Weaknesses: No injectable endotoxin-removed specifications, limited to oral raw material applications only.

3. Nuoyun Biotech (Nanjing, Scientific Research Customization Brand)

· Model: NY-HP High-Purity Research Grade (99.35%), specializing in small-batch laboratory customization;

· Strengths: Customizable crystal forms and adjustable indicators on demand;

· Weaknesses: Limited mass production capacity, extended lead times for large-volume orders.

4. Huabaiyi (Hunan, Mid-Tier Mass Production Factory)

· Model: HB-NAD985 General Domestic Standard Grade, 98.5% purity;

· Strengths: Low prices, sufficient spot inventory;

· Weaknesses: Elevated impurity levels, no injectable-grade qualifications, only suitable for ordinary health supplements.

5. Haohua Biotech (Shandong, Low-Grade Chemical Raw Material Manufacturer)

· Model: Conventional chemically synthesized 98% bulk commodity;

· Strengths: Lowest production costs;

· Weaknesses: Chemical synthesis solvent residues, failing compliance requirements for European high-end import standards.

III. Targeted Selection by HiSiaddi: Finalization of 2 Mid-to-High-End Brands and 3 Applicable Models

Combining the client’s dual product line requirements for intravenous stock solutions and capsules, Huabaiyi and Haohua (mid/low-tier manufacturers) were eliminated. Two mid-to-high-end brands (Bontai Biotech and GeneHarbor) and three applicable models were selected for implementation:

1. Bontai Biotech NAD-ER (Injectable Grade): Exclusively for the client’s German intravenous infusion stock solution production line, meeting mandatory endotoxin and USP high-purity requirements;

2. Bontai Biotech NAD-I (Clinic Grade): Backup raw material for liposome oral liquid new product lines for reserve stocking;

3. GeneHarbor GN-NAD990 (Capsule-Specific): Primary mass-production raw material for large-batch oral capsule manufacturing, balancing quality and procurement costs.

Selection Logic (Neutral Explanation from HiSiaddi)

1. Intravenous production lines mandate endotoxin removal processes, a specification exclusively available in Bontai’s ER grade with no equivalent alternatives from competing brands;

2. Mass capsule production prioritizes stable supply and cost-effectiveness, making GeneHarbor’s mass-produced full enzymatic product the optimal choice, with Bontai’s I grade as a high-end formula backup.

IV. Sample Verification and Mass Order Signing Implementation

HiSiaddi coordinated centralized shipment of samples of the three models to the German laboratory for full re-testing: Bontai NAD-ER delivered 99.42% purity and 0.07 EU/mg endotoxin, fully meeting intravenous feeding standards; GeneHarbor GN-NAD990 exhibited compliant powder angle of repose and low moisture absorption, enabling seamless automatic filling without sticking and no oxidative losses when compounded with PQQ. The client finalized a framework annual order of 620kg in one batch: 210kg Bontai ER Grade, 90kg Bontai I Grade and 320kg GeneHarbor Capsule Grade, split into 12 monthly staggered delivery batches. Compared with original Swiss imported raw materials, overall procurement costs dropped by 31%, and ocean shipping lead times were shortened from 68 days to 26 days, enabling full launch of two previously standby domestic production lines.

V. Long-Term Cooperation and Industry Summary

1. Extended Long-Term Cooperation

The VitalAge Group added customized procurement for NADH and NADP⁺ the following year, continuing to entrust HiSiaddi with supply coordination from the two selected brands. It also delegated all domestic brand screening for NMN and ergothioneine raw materials to HiSiaddi as exclusive service provider. Supported by the endorsement of this European high-end client, Bontai Biotech and GeneHarbor secured follow-up customized orders from 3 equivalent wellness brands in the Netherlands and Switzerland.

2. Industry Pain Point Summary

Driven by sales targets, domestic coenzyme raw material manufacturers only promote their own products and avoid objective disclosure of competitors’ advantages. Mid-to-high-end overseas clients lack comprehensive industry knowledge of domestic raw materials, frequently mistakenly sourcing low-grade chemically synthesized bulk goods and encountering production failures following independent procurement. Leveraging its industry database and raw material testing expertise, HiSiaddi breaks free from the single-manufacturer sales mindset to conduct neutral horizontal benchmarking of brand strengths and weaknesses, delivering graded targeted selection aligned with end-product production scenarios. It helps clients avoid costly selection errors while enabling high-quality mid-to-high-end domestic raw materials to access premium European supply chains. Contact HiSiaddi customer service for more cross-brand and cross-model comparative analysis.